Rapid uptake products

The Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date.

The 2021/22 programme builds on the successes of the previous cycle, with themes selected via an open, staged, selection process. Below is an introduction to each of the workstreams and a link to further information.

Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors

The Rapid Uptake Product (RUP) for lipid management is a novel, NICE-approved clinical pathway. This innovation aims to improve a person’s lipid profile, by reducing cholesterol concentration in blood by treating patients with the right medicine for them. There are three treatment pathways available: high intensity statins (HIST), ezetimibe, and PCSK9 inhibitors (continued from 2019/20).

Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath

FeNO testing is a method that assists with the diagnosis of asthma by measuring fractional exhaled nitric oxide (FeNO) in the breath of patients suspected of having asthma. The aim of this innovation will be to improve patient care and outcomes by more effective diagnosis of patients suspected of having asthma.

Asthma Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab

Asthma Biologics can transform patient lives by reducing asthma attacks, asthma-related hospital admissions and long-term side effects of other treatments such as oral steroids. The aim of this innovation will be to improve patient care and outcomes by improving access to biologics for people with severe asthma. The programme focuses on optimising pathways that help with the early identification of people with uncontrolled asthma, appropriate referral of patients needing further specialist input and supporting patients to self-administer their asthma biologic at home.

Tamoxifen for prevention of breast cancer for women at known risk

For women at known risk, Tamoxifen can halve the risk of breast cancer when taken over five years. However, uptake of Tamoxifen is low in clinical practice (roughly 10% in England) due to factors such as access to specialist risk assessment whereby considerations such as family history of reproductive cancers and breast density are reviewed. The aim of this innovation is to improve patient care and outcomes, and ultimately prevent avoidable breast cancer.